<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499746</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-18125-3</org_study_id>
    <secondary_id>R01DA018125</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00499746</nct_id>
  </id_info>
  <brief_title>The Discriminative Effects of Tramadol in Humans</brief_title>
  <official_title>Medications Development for Drug Abuse Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is part of a set of studies whose purpose is to test whether tramadol can be
      used for the treatment of opioid addiction. Tramadol is already available in the United
      States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may
      also have effects similar to other drugs like stimulants. The doses of tramadol used in this
      study are higher than those generally used for the treatment of pain. To be in this study a
      participant must be a user of opioids (drugs like heroin) and stimulants (drugs like
      cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and
      generally healthy. Up to 12 people will take part in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a human laboratory study that tests the effects of tramadol as a step in the possible
      development of this medication as a new treatment for opioid dependence. Tramadol is a
      mild/moderate mu agonist opioid currently marketed as an analgesic that has a unique profile
      of effects. One of the primary metabolites of tramadol, mono-O-demethyltramadol (referred to
      as M1) exerts opioid agonist effects at the mu receptor. In addition, tramadol and M1 produce
      reuptake blockade of monoamines, and this latter effect may positively influence its
      analgesic efficacy, in addition to influencing the subjective effects produced by tramadol.
      Preclinical evidence suggests that tramadol's effects on monoamine reuptake may have
      antidepressant qualities as well. Given tramadol's diverse pharmacodynamic profile, a
      systematic characterization of its subjective effects in opioid-experienced subjects would
      provide valuable information regarding its abuse liability, and its potential utility as a
      treatment for opioid dependence.

      The characterization of an opioid medication's profile can be accomplished through a variety
      of experimental procedures. One useful procedure for assessing the profile of an opioid is a
      drug discrimination procedure. In this methodology, subjects are first trained to
      discriminate reference drugs such as placebo and an opioid agonist, and then administered
      doses of a novel compound to determine how like (or unlike) it is to the reference training
      conditions. Our laboratory has a long history of using this drug discrimination methodology
      to study and to characterize opioids with varying opioid receptor activity profiles. Studies
      have generally included either two or three training conditions in humans. Using this
      technique in volunteers, studies have characterized the profile of a number of opioids
      including (for example) butorphanol, nalbuphine, pentazocine, and buprenorphine.

      While most of these studies testing the effects of mixed agonist-antagonist opioids have used
      an opioid agonist and placebo as the training conditions, tramadol's profile of effects
      suggests that there may be a non-opioid component of action at serotonin and norepinephrine
      sites that will be useful to distinguish. In particular, it is of interest to determine the
      extent to which tramadol is identified as being like a prototypic mu agonist opioid, whether
      it is substantially identified as being like a non-opioid compound, and if this non-opioid
      component is related to enhancement of monoamine effects. In order to provide a meaningful
      non-opioid contrast training condition, this study will compare different doses of tramadol
      to training conditions of placebo, a mu agonist opioid, and a prototypic stimulant.

      Overall, this evaluation will provide a greater understanding of the subjective effect
      profile of tramadol in comparison to a prototypic mu opioid and a prototypic stimulant. If
      tramadol is to be useful in the treatment of opioid dependence, a thorough assessment of its
      subjective effects in experienced opioid and stimulant abusers is warranted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test</measure>
    <time_frame>1 day</time_frame>
    <description>The acquisition of discrimination was to test whether volunteers could identify each training drug condition by the correct letter code. Results are the percentage of correct responses with a range of 0% to 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discrimination Effects Assessed by Operant Responses</measure>
    <time_frame>1 day</time_frame>
    <description>Volunteers emitted operant responses on computer keys that corresponded to the training letter, on a fixed interval 1 second schedule for 8.5 minutes. The range is from 0 to 500 operant responses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discrimination Effects Assessed by Point Distribution</measure>
    <time_frame>1day</time_frame>
    <description>In point distribution, volunteers distributed 50 points among three training drug letters depending on how certain they were of the identity of the administrated drug. Maximum total is 50 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discrimination Effects Assessed by Discrete Choice</measure>
    <time_frame>1 day</time_frame>
    <description>During discrete choice, volunteers were given three choices (placebo, hydromorphone, methylphenidate) and were asked to choose which of the training drugs they thought they received. The outcome measure illustrates the percentage of participants who chose either placebo, hydromorphone, or methylphenidate during each drug condition (i.e., Placebo, Hydromorphone 8 mg, Tramadol 50 mg, etc.), ranging from 0-100.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiologic Effects Assessed by the Pharmacological Class Questionnaire</measure>
    <time_frame>Measure at 120 min after drug administration</time_frame>
    <description>During the peak (assessed at 120 min) of each drug administration, participants were asked to complete the pharmacological class questionnaire. The pharmacological class questionnaire had volunteers indicate which drug class was most similar to the drug condition they received. Ten drug classes were listed with descriptive labels and examples of each: placebo, opiates (or opioid agonist), phenothiazines, barbiturates, antidepressants, opiate antagonists, hallucinogens, benzodiazepines, stimulants, and other. Of these choices, participants chose 3: placebo, opioid agonist, and stimulant.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Effects Assessed by Peak Change From Baseline Pupil Diameter</measure>
    <time_frame>Measure at 120 min after drug administration</time_frame>
    <description>Change in pupil diameter (mm) at peak (120 min) compared to baseline measure of pupil diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline Opioid Agonist Effects Assessed by the Visual Analog Scale (VAS)</measure>
    <time_frame>Measure at 120 min after drug administration</time_frame>
    <description>The Visual Analog Scale (VAS) measures subjective ratings of opioid agonist effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure on VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline Stimulant Effects Assessed by the Visual Analog Scale (VAS)</measure>
    <time_frame>Measure at 120 min after drug administration</time_frame>
    <description>The Visual Analog Scale (VAS) measures subjective ratings of stimulant effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Opioid Abuse</condition>
  <condition>Opioid Addiction</condition>
  <condition>Stimulant Abuse</condition>
  <condition>Stimulant Addiction</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral dose, once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral dose, once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydromorphone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral dose, once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral dose, once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tramadol</intervention_name>
    <description>oral dose, once per day</description>
    <arm_group_label>Tramadol</arm_group_label>
    <other_name>Ultram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral dose, once per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>oral dose, once per day</description>
    <arm_group_label>hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>oral dose, once per day</description>
    <arm_group_label>methylphenidate</arm_group_label>
    <other_name>stimulant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study subjects are male and female non-dependent opioid users with active stimulant
             use.

          -  Between the ages of 21-55

          -  In good physical health

          -  Without significant psychiatric illness besides their drug use.

          -  Females are required to provide a negative pregnancy test prior to study
             participation.

        Exclusion Criteria:

          -  Subjects are excluded if they have evidence of significant medical (e.g., insulin
             dependent diabetes mellitus) or psychiatric (e.g., schizophrenia) illness.

          -  Subjects with a history of seizures will be excluded.

          -  Persons with current history of significant alcohol or sedative/hypnotic drug use will
             be excluded from study participation.

          -  Applicants seeking treatment for their substance abuse will not be admitted to the
             study, and will be provided information about treatment services available.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Strain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Duke AN, Bigelow GE, Lanier RK, Strain EC. Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther. 2011 Jul;338(1):255-62. doi: 10.1124/jpet.111.181131. Epub 2011 Apr 5.</citation>
    <PMID>21467190</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>August 18, 2012</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Eric Strain, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>drug discrimination</keyword>
  <keyword>opioid pharmacology</keyword>
  <keyword>behavioral pharmacology</keyword>
  <keyword>human research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participant flow is reported in single group due to the number of randomized sequences. In Phase 1 and Phase 2, each participant received two exposures of each training drug in randomize order (placebo, Hydromorphone 8 mg, Methylphenidate 60 mg). In Phase 3, each participant received randomized exposure to placebo, Hydromorphone (4 and 8 mg), Methylphenidate (30 and 60 mg), tramadol (50, 100, 200, and 400 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1(6-9 One Day Sessions)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Failed to perform study task</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to determine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 (6-9 One Day Sessions)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3 (9-14 One Day Sessions)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test</title>
        <description>The acquisition of discrimination was to test whether volunteers could identify each training drug condition by the correct letter code. Results are the percentage of correct responses with a range of 0% to 100%.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Methylphenidate 60 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test</title>
          <description>The acquisition of discrimination was to test whether volunteers could identify each training drug condition by the correct letter code. Results are the percentage of correct responses with a range of 0% to 100%.</description>
          <units>percent of correct response</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="87.5" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="90" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Discrimination Effects Assessed by Operant Responses</title>
        <description>Volunteers emitted operant responses on computer keys that corresponded to the training letter, on a fixed interval 1 second schedule for 8.5 minutes. The range is from 0 to 500 operant responses.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Discrimination Effects Assessed by Operant Responses</title>
          <description>Volunteers emitted operant responses on computer keys that corresponded to the training letter, on a fixed interval 1 second schedule for 8.5 minutes. The range is from 0 to 500 operant responses.</description>
          <units>Responses</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.5" spread="9.6"/>
                    <measurement group_id="O2" value="116.6" spread="76.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="464.1" spread="4.2"/>
                    <measurement group_id="O7" value="341.3" spread="74.8"/>
                    <measurement group_id="O8" value="86.6" spread="62.0"/>
                    <measurement group_id="O9" value="115.6" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="341.3" spread="74.7"/>
                    <measurement group_id="O3" value="453.4" spread="9.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="118.1" spread="77.3"/>
                    <measurement group_id="O8" value="367.0" spread="60.2"/>
                    <measurement group_id="O9" value="282.9" spread="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="465.4" spread="4.7"/>
                    <measurement group_id="O5" value="465.8" spread="3.0"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="0.0" spread="0.0"/>
                    <measurement group_id="O8" value="0.0" spread="0.0"/>
                    <measurement group_id="O9" value="59.9" spread="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Discrimination Effects Assessed by Point Distribution</title>
        <description>In point distribution, volunteers distributed 50 points among three training drug letters depending on how certain they were of the identity of the administrated drug. Maximum total is 50 points.</description>
        <time_frame>1day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Discrimination Effects Assessed by Point Distribution</title>
          <description>In point distribution, volunteers distributed 50 points among three training drug letters depending on how certain they were of the identity of the administrated drug. Maximum total is 50 points.</description>
          <units>Points distributed</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="0.0"/>
                    <measurement group_id="O2" value="11.9" spread="7.8"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="50.0" spread="0.0"/>
                    <measurement group_id="O7" value="37.5" spread="8.2"/>
                    <measurement group_id="O8" value="9.4" spread="6.6"/>
                    <measurement group_id="O9" value="12.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="38.1" spread="7.8"/>
                    <measurement group_id="O3" value="50.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="12.5" spread="8.2"/>
                    <measurement group_id="O8" value="38.3" spread="6.5"/>
                    <measurement group_id="O9" value="31.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="50.0" spread="0.0"/>
                    <measurement group_id="O5" value="50.0" spread="0.0"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="0.0" spread="0.0"/>
                    <measurement group_id="O8" value="0.0" spread="0.0"/>
                    <measurement group_id="O9" value="6.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Discrimination Effects Assessed by Discrete Choice</title>
        <description>During discrete choice, volunteers were given three choices (placebo, hydromorphone, methylphenidate) and were asked to choose which of the training drugs they thought they received. The outcome measure illustrates the percentage of participants who chose either placebo, hydromorphone, or methylphenidate during each drug condition (i.e., Placebo, Hydromorphone 8 mg, Tramadol 50 mg, etc.), ranging from 0-100.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Discrimination Effects Assessed by Discrete Choice</title>
          <description>During discrete choice, volunteers were given three choices (placebo, hydromorphone, methylphenidate) and were asked to choose which of the training drugs they thought they received. The outcome measure illustrates the percentage of participants who chose either placebo, hydromorphone, or methylphenidate during each drug condition (i.e., Placebo, Hydromorphone 8 mg, Tramadol 50 mg, etc.), ranging from 0-100.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
          <units>percentage of drug identification</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="75"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="75"/>
                    <measurement group_id="O9" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylphenidate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physiologic Effects Assessed by the Pharmacological Class Questionnaire</title>
        <description>During the peak (assessed at 120 min) of each drug administration, participants were asked to complete the pharmacological class questionnaire. The pharmacological class questionnaire had volunteers indicate which drug class was most similar to the drug condition they received. Ten drug classes were listed with descriptive labels and examples of each: placebo, opiates (or opioid agonist), phenothiazines, barbiturates, antidepressants, opiate antagonists, hallucinogens, benzodiazepines, stimulants, and other. Of these choices, participants chose 3: placebo, opioid agonist, and stimulant.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
        <time_frame>Measure at 120 min after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiologic Effects Assessed by the Pharmacological Class Questionnaire</title>
          <description>During the peak (assessed at 120 min) of each drug administration, participants were asked to complete the pharmacological class questionnaire. The pharmacological class questionnaire had volunteers indicate which drug class was most similar to the drug condition they received. Ten drug classes were listed with descriptive labels and examples of each: placebo, opiates (or opioid agonist), phenothiazines, barbiturates, antidepressants, opiate antagonists, hallucinogens, benzodiazepines, stimulants, and other. Of these choices, participants chose 3: placebo, opioid agonist, and stimulant.
The outcome measure represents the percentage of participants who chose either placebo, opioid agonist, or stimulant across each drug condition.</description>
          <units>percentage of drug identification</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="75"/>
                    <measurement group_id="O8" value="37"/>
                    <measurement group_id="O9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opioid Agonist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="63"/>
                    <measurement group_id="O9" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stimulant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physiological Effects Assessed by Peak Change From Baseline Pupil Diameter</title>
        <description>Change in pupil diameter (mm) at peak (120 min) compared to baseline measure of pupil diameter</description>
        <time_frame>Measure at 120 min after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Physiological Effects Assessed by Peak Change From Baseline Pupil Diameter</title>
          <description>Change in pupil diameter (mm) at peak (120 min) compared to baseline measure of pupil diameter</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.2"/>
                    <measurement group_id="O2" value="-1.2" spread="0.2"/>
                    <measurement group_id="O3" value="-1.9" spread="0.2"/>
                    <measurement group_id="O4" value="-0.6" spread="0.3"/>
                    <measurement group_id="O5" value="-0.3" spread="0.2"/>
                    <measurement group_id="O6" value="-0.5" spread="0.1"/>
                    <measurement group_id="O7" value="-0.2" spread="0.1"/>
                    <measurement group_id="O8" value="-0.8" spread="0.3"/>
                    <measurement group_id="O9" value="-0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline Opioid Agonist Effects Assessed by the Visual Analog Scale (VAS)</title>
        <description>The Visual Analog Scale (VAS) measures subjective ratings of opioid agonist effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure on VAS.</description>
        <time_frame>Measure at 120 min after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline Opioid Agonist Effects Assessed by the Visual Analog Scale (VAS)</title>
          <description>The Visual Analog Scale (VAS) measures subjective ratings of opioid agonist effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure on VAS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.7"/>
                    <measurement group_id="O2" value="2.9" spread="1.0"/>
                    <measurement group_id="O3" value="4.8" spread="2.1"/>
                    <measurement group_id="O4" value="2.1" spread="0.5"/>
                    <measurement group_id="O5" value="3.4" spread="1.2"/>
                    <measurement group_id="O6" value="0.4" spread="0.4"/>
                    <measurement group_id="O7" value="1.6" spread="0.7"/>
                    <measurement group_id="O8" value="2.1" spread="1.0"/>
                    <measurement group_id="O9" value="3.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline Stimulant Effects Assessed by the Visual Analog Scale (VAS)</title>
        <description>The Visual Analog Scale (VAS) measures subjective ratings of stimulant effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure.</description>
        <time_frame>Measure at 120 min after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo 0 mg</title>
          </group>
          <group group_id="O2">
            <title>Hydromorphone 4 mg</title>
          </group>
          <group group_id="O3">
            <title>Hydromorphone 8 mg</title>
          </group>
          <group group_id="O4">
            <title>Methylphenidate 30 mg</title>
          </group>
          <group group_id="O5">
            <title>Methylphenidate 60 mg</title>
          </group>
          <group group_id="O6">
            <title>Tramadol 50 mg</title>
          </group>
          <group group_id="O7">
            <title>Tramadol 100 mg</title>
          </group>
          <group group_id="O8">
            <title>Tramadol 200 mg</title>
          </group>
          <group group_id="O9">
            <title>Tramadol 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline Stimulant Effects Assessed by the Visual Analog Scale (VAS)</title>
          <description>The Visual Analog Scale (VAS) measures subjective ratings of stimulant effects. The scale on this measure ranges from 0 being &quot;Not at all&quot; to 100 being &quot;Extremely&quot;. On this scale, higher scores indicate a stronger drug effect. The outcome measure illustrates a difference from peak (120 min) to baseline measure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.8"/>
                    <measurement group_id="O2" value="3.6" spread="1.0"/>
                    <measurement group_id="O3" value="3.6" spread="1.2"/>
                    <measurement group_id="O4" value="8.0" spread="1.6"/>
                    <measurement group_id="O5" value="10.6" spread="2.3"/>
                    <measurement group_id="O6" value="0.6" spread="0.4"/>
                    <measurement group_id="O7" value="0.9" spread="0.5"/>
                    <measurement group_id="O8" value="4.9" spread="2.0"/>
                    <measurement group_id="O9" value="6.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric C. Strain, M.D.</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-1191</phone>
      <email>ecsgss@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

